How to Help Your Patients Save Money on Merilog

Cost is the number-one reason patients don't fill their insulin prescriptions — or ration them once they do. For providers prescribing Merilog (Insulin Aspart-szjj), understanding the savings landscape isn't optional. It's a clinical imperative. When a patient can't afford their insulin, adherence drops, A1C rises, and downstream complications follow.

The good news: Merilog has one of the most straightforward savings programs in the insulin market right now. This guide covers every cost-reduction tool available so you can help your patients access their medication without financial hardship.

What Patients Are Actually Paying

Before diving into solutions, here's the pricing reality for Merilog in 2026:

• Retail price (no discounts): Approximately $100-$150 for a 10 mL vial (100 units/mL); $140-$200 for a carton of 5 Merilog SoloStar prefilled pens.
• With Sanofi Valyou Savings Program: $35 per 30-day supply — regardless of insurance status.
• With commercial insurance + Sanofi copay card: No more than $35 per 30-day supply.
• Medicare Part D: Capped at $35/month under the Inflation Reduction Act.
• Uninsured/underinsured with financial need: Potentially $0 through Sanofi Patient Connection.

Compare this to the broader insulin market: NovoLog vials run about $72 post-2024 price cut (though pen prices remain higher), and many rapid-acting insulins still carry list prices north of $200 without discounts. Merilog's pricing structure makes it one of the most accessible rapid-acting insulin options available.

Manufacturer Savings Programs

Sanofi Insulins Valyou Savings Program

This is the flagship program and the one most patients should know about.

• Price: $35 per 30-day supply for any combination, type, or quantity of Sanofi insulins (including Merilog, Lantus, Toujeo, Admelog, and Apidra).
• Eligibility: All patients regardless of income or insurance status. Effective January 1, 2026.
• How to enroll: Patients can sign up at insulinvalyou.com or by calling Sanofi directly. No income verification required.
• Clinical note: Because the program covers all Sanofi insulins at the same $35 rate, patients using Merilog alongside Sanofi basal insulins (like Lantus or Toujeo) get a particularly good deal — the cap applies to any combination.

Sanofi Insulins Copay Savings Program

• For: Commercially insured patients.
• Benefit: Copay capped at $35 per 30-day supply.
• How it works: Functions as a copay card that covers the difference between the patient's insurance copay and $35.
• Limitation: Not valid for patients on government insurance (Medicare, Medicaid, Tricare).

Sanofi Patient Connection

• For: Uninsured or underinsured patients with demonstrated financial need.
• Benefit: Merilog provided at no cost.
• How to apply: Patients or providers can apply at sanofipatientconnection.com or call 1-888-847-4877.
• Documentation: Typically requires proof of income and insurance status.
• Clinical note: This program is critical for your patients who fall through the cracks — those without insurance who may not qualify for other assistance. Have your staff keep applications on hand.

Coupon and Discount Card Options

Beyond manufacturer programs, several third-party discount platforms can help reduce costs:

• GoodRx — Shows pharmacy-specific pricing and provides coupons. Useful for comparing prices across pharmacies in your patient's area.
• SingleCare — Another coupon platform that negotiates pharmacy pricing. Can sometimes beat GoodRx prices depending on the pharmacy.
• RxSaver — Compares prices across nearby pharmacies and offers downloadable coupons.
• InsideRx — A Sanofi-affiliated discount program that may offer additional savings at participating pharmacies.

For most patients, the Sanofi Valyou program at $35/month will be the best option. Coupon cards are most useful for patients who haven't enrolled in the manufacturer program or who need a one-time fill while waiting for enrollment to process.

Insurance and Government Program Considerations

Commercial Insurance

Formulary placement for Merilog varies by plan. As a new biosimilar, payers are still evaluating where to place it. Some plans may require prior authorization or step therapy (trying NovoLog or another rapid-acting insulin first). When you encounter a PA requirement:

• Document the clinical rationale for Merilog specifically (e.g., patient established on Insulin Aspart, Sanofi insulin ecosystem for basal-bolus, cost considerations)
• Reference the biosimilar status and FDA approval (February 14, 2025)
• Note the Valyou Savings Program as a backup if the PA is denied

Medicare Part D

Under the Inflation Reduction Act, all Medicare Part D beneficiaries have a $35/month cap on insulin copays. This applies to Merilog regardless of the plan's formulary tier. However, some plans may still require prior authorization for biosimilar insulins. Advise your Medicare patients that the $35 cap is their right by law.

Medicaid

Medicaid coverage varies by state, but most state Medicaid programs cover insulin products with little to no copay. Merilog's biosimilar status may actually give it preferred formulary placement in states that prioritize lower-cost alternatives.

Generic Alternatives and Therapeutic Substitution

While Merilog is already the lower-cost biosimilar option in the Insulin Aspart space, here's how the rapid-acting insulin landscape looks for cost-conscious prescribing:

• Merilog (Insulin Aspart-szjj) — $35/month via Valyou. Biosimilar to NovoLog.
• NovoLog (Insulin Aspart) — Reference product. Vial price reduced to ~$72 in 2024. Pens remain more expensive.
• Unbranded Insulin Aspart (Novo Nordisk) — Was available as a lower-cost option but is being discontinued December 31, 2025. Patients on this product need to transition.
• Humalog (Insulin Lispro) — Different rapid-acting analog. Eli Lilly has reduced prices significantly, with authorized generics available.
• Admelog (Insulin Lispro, Sanofi) — Biosimilar to Humalog. Also covered under the Sanofi Valyou program at $35/month.
• Insulin Lispro (authorized generic) — Available from Eli Lilly at reduced cost.

For patients currently on the discontinued unbranded Insulin Aspart, Merilog is the most natural transition — same molecule, same drug class, with a strong savings program. For a detailed comparison, see the patient-facing alternatives guide.

Building Cost Conversations Into Your Workflow

Research consistently shows that patients don't bring up cost concerns unless asked. Here are practical ways to integrate cost discussions into your practice:

At Prescribing

• Ask about cost barriers — "Do you have any concerns about affording this medication?" A direct question opens the door.
• Mention the $35 program upfront — When prescribing Merilog, tell patients about the Valyou Savings Program before they leave. Don't assume they'll find it on their own.
• Provide enrollment information — Keep printed cards or QR codes in exam rooms that link to insulinvalyou.com. Have your MA or nurse hand them out with the prescription.

At Follow-Up

• Ask about adherence — "Have you been able to fill and take your Merilog as prescribed?" If not, cost is often the reason.
• Check for rationing — Insulin rationing is more common than most providers realize. Ask specifically: "Have you ever had to stretch your insulin to make it last longer?"
• Reassess savings programs — Insurance changes, income changes, and program updates happen. Review financial access at least annually.

Staff Training

• Train front-desk and nursing staff on the Sanofi savings programs so they can answer basic questions.
• Designate a team member to handle prior authorizations and patient assistance program applications.
• Keep a quick-reference sheet of insulin savings programs (not just Merilog — all major insulins) posted in the prescribing area.

Use Medfinder for Provider Resources

Medfinder for Providers helps you and your staff check pharmacy availability for Merilog and other hard-to-find medications, saving time when patients report stock issues. It's a free tool designed to support clinical workflows around medication access.

Final Thoughts

The insulin affordability crisis hasn't been solved, but it's getting better — and Merilog is part of that progress. At $35/month through the Valyou Savings Program, with a robust patient assistance program for those who need it, Merilog removes many of the cost barriers that have historically undermined insulin adherence.

As a provider, the most impactful thing you can do is make cost a routine part of the prescribing conversation. Ask the question. Share the program. Follow up. Your patients' A1C — and their quality of life — will reflect it.

For patient-facing resources on Merilog pricing, share our patient savings guide. For pharmacy stock checks, visit Medfinder for Providers.